Food and Drug Administration
Cardiovascular and Renal Drugs Advisory Committee
July 18, 2002
Morning Session
NDA 20-838/S-015 ATACAND® (candesartan cilexetil)
Disclaimer
The statements contained in this document(s) are those of the product's sponsor,
not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA
has not made a final determination about the safety or effectiveness of the
product described in this document.
Background Information, AstraZeneca LP pdf
Food and Drug Administration Briefing Information
Statistical Review and Evaluation pdf htm doc
Clinical Pharmacology and Biopharmaceutics Review pdf htm doc